Studies ovarian cancer patients by their homologous recombination gene status
Follows adults with newly treated ovarian cancer, grouped by BRCA and HRD gene status.
Plain-language title generated from the registry record
Registry title: Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Key facts
- Where
- København Ø, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT05574673, who can take part
Where in Denmark
- RigshospitaletKøbenhavn Ø, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- Trial code
- NCT05574673
- Record updated
- 27 February 2026
- Original description
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.Read full original descriptionShow less
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype - A Prospective Observational Study
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
Patients are eligible to be included in the study, if all the following inclusion criteria are met:; Patients with newly diagnosed histologically confirmed epithelial ovarian cancer:; FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA); FIGO stage III-IV of any histology; Women aged ≥18 years of age at the time of diagnosis; Patients intended for platinum-based chemotherapy treatment; Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol; Patients consent to provide archival tumor tissue sample; Patients are ineligible to be included in the study, if any of the exclusion criteria are met:; Non-epithelial ovarian cancer, borderline tumors, or mucinous histology; Patients with FIGO stage I-II, BRCAwt ovarian cancer.